1. In Vivo
  2. >>Innovation

Hemophilia In Transition: Can Next-Gen Products Wake A Sleepy Market?

The hemophilia market could be about to undergo a wave of innovation not seen since the introduction of recombinant factor 20 years ago in response to a crisis in contaminated plasma products. Over the next three years, long-acting factor products may have an even more transformative effect on the market, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market. But will the improvements be enough to sway providers and payors?

The hemophilia market is about to undergo a wave of innovation not seen since the introduction of recombinant blood clotting factors 20 years ago. Over the next three years, long-acting (LA) factor products may have an even greater transformative effect, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market.

LA products will also change the competitive landscape. Established companies like Pfizer Inc. (via its inheritance of Wyeth’s BeneFIX...

More from Innovation

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By Ashley Yeo

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

More from In Vivo

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.